A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab

(2020) Kristine A. Frerichs et al.   CLINICAL CANCER RESEARCH

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

(2020) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

(2020) Dimitris Skokos et al.   Science Translational Medicine

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

(2020) Chiara Caraccio et al.   Frontiers in Immunology

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies

(2019) Nathan D. Trinklein et al.   mAbs

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

(2019) Jie Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bispecific antibodies: a mechanistic review of the pipeline

(2019) Aran F. Labrijn et al.   NATURE REVIEWS DRUG DISCOVERY

A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer

(2019) Alison Crawford et al.   Science Translational Medicine

Clinical lessons learned from the first leg of the CAR T cell journey

(2019) Robbie G. Majzner et al.   NATURE MEDICINE

CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity

(2019) Ji Li et al.   Science Translational Medicine

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

(2019) Rachel Grosser et al.   CANCER CELL

How to Train your T cells: Overcoming Immune Dysfunction in Multiple Myeloma

(2019) Adam D Cohen et al.   CLINICAL CANCER RESEARCH

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives

(2019) Mohamad Mohty et al.   LEUKEMIA

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

(2018) Olivia Campagne et al.   CLINICAL CANCER RESEARCH

Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells

(2018) Kevin M. Friedman et al.   HUMAN GENE THERAPY

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

(2018) Rosemarie Tremblay-LeMay et al.   Journal of Hematology & Oncology

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function

(2018) Alexander I. Salter et al.   Science Signaling

PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients

(2018) Anne-Marit Sponaas et al.   Oncotarget

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

(2018) Shih-Feng Cho et al.   Frontiers in Immunology

Redirected T Cell Cytotoxicity in Cancer Therapy

(2018) Raphael A. Clynes et al.   Annual Review of Medicine

CD3-bispecific antibody therapy turns solid tumors into inflammatory sites but does not install protective memory

(2018) Hreinn Benonisson et al.   MOLECULAR CANCER THERAPEUTICS

Mouse Models for Cancer Immunotherapy Research

(2018) Brian Olson et al.   Cancer Discovery

Allogeneic CAR-T Cells: More than Ease of Access?

(2018) Charlotte Graham et al.   Cells

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

(2017) S K Kumar et al.   LEUKEMIA

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

(2017) S Hipp et al.   LEUKEMIA

Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?

(2016) Jacalyn Rosenblatt et al.   BLOOD

Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity

(2016) Andrew D. Tustian et al.   mAbs

T Cell Redirecting Therapies for Cancer Treatment

(2015) Barbra Sasu et al.   CURRENT CANCER DRUG TARGETS

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

Novel immunotherapies in lymphoid malignancies

(2015) Connie Lee Batlevi et al.   Nature Reviews Clinical Oncology

γ-secretase directly sheds the survival receptor BCMA from plasma cells

(2015) Sarah A. Laurent et al.   Nature Communications

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys

(2015) Eric J. Smith et al.   Scientific Reports

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

(2014) A. J. Murphy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic Advancements in Multiple Myeloma

(2014) Alessandro Gozzetti et al.   Frontiers in Oncology

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

(2013) R. O. Carpenter et al.   CLINICAL CANCER RESEARCH

Blinatumomab: A historical perspective

(2012) Dirk Nagorsen et al.   PHARMACOLOGY & THERAPEUTICS

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110

(2009) Cornelia Haas et al.   IMMUNOBIOLOGY